Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRADIOL VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRADIOL VALERATE.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Estradiol valerate is a prodrug of estradiol, a natural estrogen. Estrogens exert their effects by binding to estrogen receptors (ERα and ERβ), which act as transcription factors regulating gene expression. This leads to proliferation and growth of reproductive tissues, modulation of gonadotropin secretion, and effects on bone density, lipid metabolism, and other tissues.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1-2 mg orally once daily adjusted based on response; for hormone therapy, 5-20 mg intramuscularly every 4 weeks.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal elimination half-life is approximately 12-14 hours after intramuscular administration, allowing for weekly or biweekly dosing intervals.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Renal (approximately 50% as glucuronide and sulfate conjugates), biliary/fecal (approximately 30-40% as conjugates), with enterohepatic circulation.
Category D/X
Category D/X
Progestin + Estrogen
Estrogen